Development of AAV vectors for long-term expression of eCD4-Ig
Development of AAV vectors for long-term expression of eCD4-Ig
批准号:
9979748
负责人:
MICHAEL DAVID ALPERT
金额:
$99.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2021-07-31
关键词:
AffinityAntibodiesAntibody FormationAntibody ResponseAntigen-Presenting CellsAntiviral AgentsBindingCCR5 geneCMV promoterDependovirusDevelopmentDoseEngineeringEnhancersEnzymesEpitopesExhibitsGene ExpressionGlycoproteinsGrantHIVHIV-1Healthcare SystemsHuman T-lymphotropic virus 1Immune responseImmunoglobulin Constant RegionImmunoglobulin Somatic HypermutationImmunologicsIn VitroInfectionInnate Immune ResponseInternal Ribosome Entry SiteIntramuscular InjectionsIntravenousIntronsLaboratory AnimalsLifeLongevityMacacaMacaca mulattaMethylationMuscleMuscle CellsNaturePatientsPeptide HydrolasesPlasmaPolyadenylationPost-Translational Protein ProcessingPrimatesProductionResearchRiskSimian virus 40SiteStructureT cell responseTestingTimeTransgenesViralVirus Receptorsadeno-associated viral vectorbasecellular transductioncostdesignexpression vectorfitnessgene transfer vectorglobal healthimmunogenicimmunogenicityimprovedinnovationneutralizing antibodynovelpandemic diseasepeptidomimeticspreventpromoterprotein-tyrosine sulfotransferase 2public health relevancereceptorsimian human immunodeficiency virussynthetic antibodiestranscription factortransgene expressionvectorvector genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT / SUMMARY / PROJECT DESCRIPTION
A single intramuscular injection of an adeno-associated virus (AAV) vector that expresses eCD4-Ig has the
potential to treat or prevent HIV-1 infection for a lifetime. eCD4-Ig is a synthetic antibody or “immunoadhesin”
constructed by fusing parts of the viral receptor (CD4) and coreceptor (CCR5) to the constant region of an
antibody. Because eCD4-Ig binds the HIV-1 envelope glycoprotein (Env) through the same contacts used by
Env to recognize its receptor and coreceptor, eCD4-Ig neutralizes 100% of HIV-1 isolates and presents
fundamental barriers to viral escape. We have previously shown that rhesus macaques inoculated with AAV
expressing eCD4-Ig exhibited sterilizing protection against high-dose intravenous challenges with simian-
human immunodeficiency virus (SHIV). Now, we propose several practical innovations designed to maximize
the concentrations of eCD4-Ig in plasma that are sustained over the long term by AAV-transduced muscle.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
-
批准号:10867558
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2023
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Process development for manufacturing eCD4-Ig
-
批准号:10603836
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2023
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Glycoengineering eCD4-Ig
-
批准号:10589151
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2022
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Glycoengineering eCD4-Ig
-
批准号:10549884
-
项目类别:
-
资助金额:$97.47万
-
财政年份:2022
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Glycoengineering eCD4-Ig
-
批准号:10326424
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2021
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Engineering AAV capsids for enhanced transduction of skeletal muscle
-
批准号:10515802
-
项目类别:
-
资助金额:$101.22万
-
财政年份:2020
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Engineering AAV capsids for enhanced transduction of skeletal muscle
-
批准号:10080465
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2020
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Project 3:Optimal use of ART in establishing functional cures
-
批准号:10381479
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2020
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Project 3:Optimal use of ART in establishing functional cures
-
批准号:10625290
-
项目类别:
-
资助金额:$33.41万
-
财政年份:2020
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Engineering AAV capsids for enhanced transduction of skeletal muscle
-
批准号:10576418
-
项目类别:
-
资助金额:$101.22万
-
财政年份:2020
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig
-
批准号:10394340
-
项目类别:
-
资助金额:$90.74万
-
财政年份:2020
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Development of AAV vectors for long-term expression of eCD4-Ig
-
批准号:9770769
-
项目类别:
-
资助金额:$99.97万
-
财政年份:2017
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?
-
批准号:9390589
-
项目类别:
-
资助金额:$93.72万
-
财政年份:2016
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Development of a synthetic antibody based on the HIV receptor and co-receptor that is optimized for highly efficient killing of HIV-infected cells by ADCC
-
批准号:8992832
-
项目类别:
-
资助金额:$22.39万
-
财政年份:2015
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
Project 3:Optimal use of ART in establishing functional cures
-
批准号:9891596
-
项目类别:
-
资助金额:$37.13万
-
财政年份:--
-
负责人:MICHAEL DAVID ALPERT
-
依托单位:
海外基金